AbbVie
“At AbbVie, we are committed to improving outcomes for patients with multiple myeloma (MM) and recognize that addressing the toughest healthcare challenges requires a dynamic and robust collaborative approach. We are excited to partner with the Foundation for the National Institutes of Health’s (FNIH) Biomarkers Consortium on this project aimed to better identify patients at risk for progression to MM that can hopefully guide therapeutic opportunities for precision interception leading to better outcomes in patients with precursor conditions.”
Raluca Verona
Head of Precision Medicine Oncology
AbbVie
Adaptive Biotechnologies
“Adaptive is honored to partner with the FNIH and other innovators to address the unmet needs of patients with myeloma precursor conditions. Through this project, we aim to further characterize the value that measurable residual disease (MRD) testing with clonoSEQ can bring across the myeloma management continuum – from early risk stratification to monitoring to interventional guidance throughout the patient journey. We are eager to explore how clonoSEQ can add insight to the clinical assessment of MGUS and SMM patients, and in particular how testing can reduce or alleviate the ongoing uncertainty that so many patients with these diagnoses face.”
Susan Bobulsky
Chief Commercial Officer, MRD
Adaptive Biotechnologies
Regeneron
“At Regeneron, we have always had a highly collaborative approach and prioritize investing in foundational research and technologies, recognizing that only through a deep understanding of underlying biology can we address these diseases. We are proud to expand our collaboration with the FNIH and be part of this initiative that aims to develop prognostic biomarkers and monitoring tools for monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM). These are typically precancerous conditions that can lead to multiple myeloma, so efforts to accurately define those at risk and assess early interventions, enables the potential to stop this devastating disease.”
Karen Rodriguez Lorenc, MD
Vice President, Global Program Head, Hematology
Regeneron
10x Genomics, Inc.
“We are proud to partner with the FNIH Biomarkers Consortium on this vital project, which we believe will help establish single cell analysis as an essential method for biomarker discovery and validation. This unique collaboration between academia, industry and government has the potential to transform our understanding of multiple myeloma and ultimately transform patient care.”
Rena Bradham
VP and Head of Global Marketing
10x Genomics, Inc.